Symbicort SMART Satisfaction From Patient Perspective 2009

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00946452
First received: July 24, 2009
Last updated: March 17, 2010
Last verified: March 2010
  Purpose

To characterize the level of asthma control and patient satisfaction amongst diagnosed asthma sufferers who are currently receiving Symbicort Maintenance and Reliever Therapy (SMART) in Malaysia.


Condition
Asthma

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Symbicort SMART Satisfaction From Patient Perspective 2009

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Score level of Satisfaction in Asthma Treatment Questionnaire (SATQ) [ Time Frame: After 3 months on SMART - once ] [ Designated as safety issue: No ]
  • Score level of Asthma Control Test (ACT) [ Time Frame: After 3 months on SMART - once ] [ Designated as safety issue: No ]

Enrollment: 205
Study Start Date: August 2009
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 59 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Primary care clinic

Criteria

Inclusion Criteria:

  • Have been prescribed Symbicort SMART (1 or 2 inhalation twice daily) by their Dr's for the past 3 months
  • Informed consent

Exclusion Criteria:

  • Symbicort SMART treatment < 3 months
  • Patients requiring short courses of oral steroids more than twice in a month
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00946452

Locations
Malaysia
Research Site
Petaling Jaya, Selangor, Malaysia
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Liam Chong Kin, Professor UMMC
  More Information

No publications provided

Responsible Party: MC MD, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00946452     History of Changes
Other Study ID Numbers: NIS-RMY-SYM-2009/1
Study First Received: July 24, 2009
Last Updated: March 17, 2010
Health Authority: Malaysia: Ministry of Health

Keywords provided by AstraZeneca:
Control
Satisfaction

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Symbicort
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 22, 2014